The resolution urges the United States Supreme Court to protect reproductive rights, specifically regarding the use and access to mifepristone, a medication used for medical termination of pregnancy and treatment of miscarriages. It highlights the crisis in women's health care following the Supreme Court's 2022 decision to overturn Roe v. Wade, which has led to increased restrictions on reproductive rights and access to essential medical care. The resolution points out conflicting federal court rulings regarding mifepristone's approval by the FDA, emphasizing the need for the Supreme Court to intervene and provide clarity on the legality of the drug's use.

Furthermore, the resolution calls for the Supreme Court to respect the expertise of medical providers and the scientific community, affirm the freedom of individuals to make personal health care decisions without undue government interference, and ensure the safety of those seeking reproductive health care. It underscores the potential consequences of restricting access to mifepristone, which could affect millions of women and emphasizes the importance of maintaining established medical standards in the face of judicial challenges. Copies of the resolution will be sent to the Chief Justice of the Supreme Court and all members of Congress from New Jersey.